Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Perrone, Ronald"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł :
Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD.
Autorzy :
Mallett AJ; Institute for Molecular Bioscience and Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.; Department of Renal Medicine, Townsville University Hospital, Townsville, Queensland, Australia.
Perrone RD; Division of Nephrology, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA.
Rangan G; Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.; Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, New South Wales, Australia.
Hawley C; Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.; Translational Research Institute, Brisbane, Queensland, Australia.
El-Damanawi R; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.; Cambridge Clinical Trials Unit, Addenbrooke's Hospital, Cambridge, UK.
Hiemstra TF; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.; Cambridge Clinical Trials Unit, Addenbrooke's Hospital, Cambridge, UK.
Arellano CT; Institute for Molecular Bioscience and Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Lee J; Biostatistics, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.
Torres VE; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
Kidney international reports [Kidney Int Rep] 2021 Feb 02; Vol. 6 (4), pp. 1032-1040. Date of Electronic Publication: 2021 Feb 02 (Print Publication: 2021).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
Autorzy :
Irazabal MV; Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Blais JD; Otsuka Pharmaceutical Development and Commercialization Inc.; Global Medical Affairs, Princeton, NJ.
Perrone RD; Tufts Medical Center; Boston, Massachusetts, USA.
Gansevoort RT; University Medical Center, Groningen, Netherlands.
Chapman AB; Division of Nephrology, University of Chicago, Chicago, Illinois, USA.
Devuyst O; Institute of Physiology, University of Zurich, Zurich, Switzerland.
Higashihara E; Department of Urology, Kyorin University School of Medicine, Mitaka, Japan.
Harris PC; Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Zhou W; Otsuka Pharmaceutical Development and Commercialization Inc., Biostatistics, Rockville, Maryland, USA.
Ouyang J; Otsuka Pharmaceutical Development and Commercialization Inc., Biostatistics, Rockville, Maryland, USA.
Czerwiec FS; Otsuka Pharmaceutical Development and Commercialization Inc., Global Clinical Development, Rockville, Maryland, USA.
Torres VE; Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
Kidney international reports [Kidney Int Rep] 2016 Aug 06; Vol. 1 (4), pp. 213-220. Date of Electronic Publication: 2016 Aug 06 (Print Publication: 2016).
Typ publikacji :
Journal Article
Czasopismo naukowe
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies